Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) stock drops despite market gains: Important facts to note
Recursion Pharmaceuticals (RXRX) ended the recent trading session at $4.65, demonstrating a -4.12% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.26%.
Amber Implants, a Netherlands medtech developing next-generation implants for spinal injuries, named Vincent Gardès as CEO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback